Haptoglobin phenotype and epithelial ovarian cancer

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4353-4358

  Mandato, Vincenzo Dario ^a   Magnani, Elena ^a   Abrate, Martino ^a   Casali, Bruno ^a   Nicoli, Davide ^a   Farnetti, Enrico ^a   Formisano, Debora ^a   Pirillo, Debora ^a   Ciarlini, Gino ^a   De Iaco, Pierandrea ^b   Strada, Isabella ^b   Zamagni, Claudio ^b   La Sala, Giovanni Battista ^a,c  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cancer biomarkers; Epithelial ovarian cancer; Haptoglobin phenotypes

Indexed keywords

ANTINEOPLASTIC AGENT; HAPTOGLOBIN; TUMOR MARKER;

ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADULT; ALLELE; ARTICLE; BLOOD ANALYSIS; BLOOD STORAGE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIOID CARCINOMA; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPTOGLOBINS; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN ISOFORMS;

EID: 84867835307     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007. (Pubitemid 46359643)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Murray T: Cancer statistics. CA Cancer J Clin 58: 71-96, 2008.
3. Whittemore AS, Gong G and Itnyre J: Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 60: 496-504, 1997. (Pubitemid 27097597)
4. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, vander Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group: NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363: 943-953, 2010.
5. Clarke-Pearson DL: Clinical practice. Screening for ovarian cancer. N Engl J Med 361: 170-177, 2009.
6. Chitale R: Monitoring ovarian cancer: CA125 trial stirs controversy. J Natl Cancer Inst 101: 1233-1235, 2009.
7. Bast RC Jr.: CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 116: 2850-2853, 2010.
8. Goldman PA: CA 125: Value or addiction? Cancer 116: 2854-2855, 2010.
9. Mueller WK, Handschumacher R and Wade ME: Serum haptoglobin in patients with ovarian malignancies. Obstet Gynecol 38: 427-435, 1971.
10. Yang SE, Min WK, Park H, Chun S, Nah J and Kim JQ: Distribution of haptoglobin phenotypes in a Korean population, using the semi-automated PhastSystem. Ann Clin Biochem 37: 205-209, 2000. (Pubitemid 30122246)
11. Beckman G, Eklund A, Frohlander N and Stjernberg N: Haptoglobin groups and lung cancer. Hum Hered 36: 258-260, 1986. (Pubitemid 16048381)
12. Benkmann HG, Hanssen HP, Ovenbeck R and Goedde HW X: Distribution of alpha-1-antitrypsin and haptoglobin phenotypes in bladder cancer patients. Hum Hered 37: 290-293, 1987. (Pubitemid 17140371)
13. Mitchell RJ, Carzino R and Janardhana V: Associations between the two serum proteins haptoglobin and transferrin and leukaemia. Hum Hered 38: 144-150, 1988.
14. Awadallah SM and Atoum MF: Haptoglobin polymorphism in breast cancer patients form Jordan. Clin Chim Acta 341: 17-21, 2004. (Pubitemid 38210309)
15. Epelbaum R, Shalitin C, Segal R, Valansi C, Arselan I, Faraggi D, Leviov M, Ben-Shahar M and Haim N: Haptoglobin-related protein as a serum marker in malignant lymphoma. Pathol Oncol Res 4: 271-276, 1998. (Pubitemid 29081097)
16. Dunzendorfer U, Jung K and Ohlenschlager G: Transferrin: C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors. Eur Urol 6: 232-236, 1980.
17. An JY, Fan ZM, Zhuang ZH, Qin YR, Gao SS, Li JL and Wang LD: Proteomic analysis of blood level of proteins before and after operation in patients with esophageal squamous cell carcinoma at highincidence area in Henan Province. World J Gastroenterol 10: 3365-3368, 2004. (Pubitemid 39585484)
18. Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA and Rice GE: Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 5: 4625-4636, 2005. (Pubitemid 41739939)
19. Ahmed N, Barker G, Oliva KT, Hoffmann P, Riley C, Reeve S, Smith AI, Kemp BE, Quinn MA and Rice GE: Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer 91: 129-140, 2004. (Pubitemid 39013057)
20. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS and Mok SC: Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9: 2904-2911, 2003. (Pubitemid 36993248)
21. Zhao C, Annamalai L, Guo C, Kothandaraman N, Koh SC, Zhang H, Biswas A and Choolani M: Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 9: 1-7, 2007. (Pubitemid 46203929)
22. Dobryszycka W and Warwas M: Haptoglobin types in ovarian tumors. Neoplasma 30: 169-172, 1983. (Pubitemid 13027464)
23. Arredouani M, Matthijs P, Van Hoeyveld E, Kasran A, Baumann H, Ceuppens JL and Stevens E: Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release. Immunology 108: 144-151, 2003. (Pubitemid 36232863)
24. Tseng CF, Lin CC, Huang HY, Liu HC and Mao SJ: Antioxidant role of human haptoglobin. Proteomics 4: 2221-2228, 2004. (Pubitemid 39025321)
25. Quaye IK: Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 102: 735-742, 2008.
26. Dahlqvist SR and Fröhlander N: Haptoglobin groups and rheumatoid arthritis. Hum Hered 35: 207-211, 1985. (Pubitemid 15233437)
27. Rantapãã Dahlqvist s, Beckman G and Beckman L: Serum protein markers in systemic lupus erythematosus. Hum Hered 38: 44-47, 1988.
28. McGuirk J, Hao G, Hou W, Abhyankar S, Williams C, Yan W, Yuan J, Guan X, Belt R, Dejarnette S, Wieman J and Yan Y: Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation. J Hematol Oncol 2: 17, 2009.
29. Quaye IK, Agbolosu K, Ibrahim M and Bannerman-Williams P: Haptoglobin phenotypes in cervical cancer: Decreased risk for Hp2-2 individuals. Clin Chim Acta 403: 267-268, 2009.
30. Mahmud SM, Koushik A, Duarte-Franco E, Costa J, Fontes G, Bicho M, Coutlée F, Franco EL; Biomarkers of Cervical Cancer Risk Study Team: Haptoglobin phenotype and risk of cervical neoplasia: A case-control study. Clin Chim Acta 385: 67-72, 2007. (Pubitemid 47374668)
31. Yigit R, Massuger LF, Figdor CG and Torensma R: Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 117: 366-372, 2010.
32. Giuntoli RL 2nd, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE and Oelke M: Ovarian cancer-associated ascites demonstrates altered immune environment: Implications for antitumor immunity. Anticancer Res 29: 2875-2884, 2009.
33. Quesnel B: Tumor dormancy and immunoescape. APMIS 116: 685-694, 2008.
34. Hicklin DJ, Marincola FM and Ferrone S: HLA class I antigen down-regulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5: 178-186, 1999. (Pubitemid 29279236)
35. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M and Duggan-Keen M: Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18: 89-95, 1997. (Pubitemid 27107103)
36. Liu Z, Guo B and Lopez RD: Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: Implications in the design of gammadelta-T-cell based immunotherapies for pancreatic cancer. J Gastroenterol Hepatol 24: 900-911, 2009.
37. Piali L, Hammel P, Uherek C, Bachmann F, Gisler RH, Dunon D and Imhof BA: CD31/PECAM- 1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol 130: 451-460, 1995.
38. Igney FH and Krammer PH: Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 71: 907-920, 2002.
39. Lee CC, Lin HY, Hung SK, Li DK, Ho HC, Lee MS, Tung YT, Chou P and Su YC: Haptoglobin genotypes in nasopharyngeal carcinoma. Int J Biol Markers 24: 32-37, 2009.
40. Samak R, Edelstein R and Israel L: Immunosuppressive effect of acute-phase reactant proteins in vitro and its relevance to cancer. Cancer Immunol Immunother 13: 38-43, 1982. (Pubitemid 12081460)
41. Oh S, Very D, Walker J, Raam S and Ju ST: An analogy between fetal haptoglobin and a potent immunosuppressant in cancer. Cancer Res 47: 5120-5126, 1987. (Pubitemid 17146483)